Analysts Set Celcuity, Inc. (NASDAQ:CELC) Price Target at $152.09

Celcuity, Inc. (NASDAQ:CELC) has been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $152.0909.

Several research firms have commented on CELC. Wolfe Research reissued an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a research report on Thursday, March 12th. Craig Hallum decreased their target price on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Citizens Jmp boosted their price objective on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research note on Monday, May 4th. Finally, Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a research note on Monday, May 4th.

Celcuity Stock Performance

CELC stock opened at $104.62 on Wednesday. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of -26.83 and a beta of 0.10. Celcuity has a 12 month low of $12.48 and a 12 month high of $151.02. The firm has a 50 day moving average of $113.66 and a two-hundred day moving average of $110.60.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities analysts anticipate that Celcuity will post -3.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by insiders.

Institutional Trading of Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of the company. NEA Management Company LLC lifted its stake in shares of Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after buying an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC acquired a new position in Celcuity during the 4th quarter valued at $310,302,000. Soleus Capital Management L.P. raised its stake in Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the last quarter. Vanguard Group Inc. raised its stake in Celcuity by 10.7% during the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock valued at $227,351,000 after purchasing an additional 220,386 shares during the last quarter. Finally, State Street Corp raised its stake in Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after purchasing an additional 914,887 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.